Endometrial Cancer Archives - Page 2 of 8

Oral bisphosphonates may greatly reduce the risk of endometrial cancer.

Peritoneal Cytology Prognostic in Stage II-III Endometrial Cancer

By

Leah Lawrence

April 23, 2021

Researchers found that the benefit of adjuvant therapy differed depending on the status of peritoneal cytology in women with endometrial cancer.

Gynecologic Cancer

Intrauterine Levonorgestrel Showed Activity in Endometrial Adenocarcinoma

By

Andrea S. Blevins Primeau, PhD, MBA

April 22, 2021

Researchers sought to determine if LNG-IUD is effective and whether the addition of weight loss or metformin can further improve response in patients with EAC and EHA.

Investigators of the observational study sought to clarify the time-dependent effects between long-term oral contraceptive use and risk for breast, ovarian, and endometrial cancer risk.

Gynecologic Cancer

Oral Contraceptives Found to Protect Against Ovarian and Endometrial Cancer for up to 35 Years After Discontinuation

By

Julia Faith Sklar

January 19, 2021

Investigators of the observational study sought to clarify the time-dependent effects between long-term oral contraceptive use and risk for breast, ovarian, and endometrial cancer risk.

Use of power morcellation to remove fibroids in the uterus can end up spreading bits of hidden cance

SITC 2020

Retifanlimab Demonstrated Antitumor Activity in MSI-H/dMMR Endometrial Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

November 13, 2020

The PD-1 inhibitor retifanlimab showed antitumor activity with a tolerable safety profile among patients with MSI-H/dMMR endometrial cancer.

This article reviews the current evidence for the role of aromatase inhibitors (AIs) in the treatmen

Gynecologic Cancer

Clinical Trial: Combination of Letrozole Plus Abemaciclib in Estrogen Receptor–Positive Endometrial Cancer

By

Cancer Therapy Advisor Staff

October 26, 2020

Does abemaciclib and letrozole effective slow or stop endometrial cancer cell growth?

The researchers found 21 early-onset cancer cases carrying the novel pathogenic TP53 variant.

Gynecologic Cancer

Clinical Trial: Mirvetuximab Soravtansine and Pembrolizumab in Endometrial Cancer

By

Cancer Therapy Advisor Staff

October 26, 2020

All patients will receive mirvetuximab soravtansine and pembrolizumab in this study.

In women, the association between obesity and endometrial cancer is stronger than in any other type

Gynecologic Cancer

Trial to Evaluate PORTEC-4a: Molecular Profile-Based vs Standard Adjuvant Radiotherapy in Endometrial Cancer

By

Cancer Therapy Advisor Staff

October 26, 2020

A phase 3 study seeks to evaluate the value of selecting therapy based on molecular profiling.

ASCO and the Society of Gynecologic Oncology jointly issued new clinical practice guidelines for the

Gynecologic Cancer

Clinical Trial: Phase 3 AtTEnd Trial in Endometrial Cancer

By

Cancer Therapy Advisor Staff

October 26, 2020

Patients with advanced or recurrent endometrial cancer enrolled in the experimental arm will receive atezolizumab in combination with paclitaxel and carboplatin.

ESMO Virtual Congress 2020